Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies

American Journal of Pathology

Volumn 168, Issue 5, 2006, Pages 1666-1675

  Zubieta, Mariana Rodríguez ^a   Furman, David ^b   Barrio, Marcela ^b   Bravo, Alicia Inès ^c   Domenichini, Enzo ^d   Mordoh, José ^a,b  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^b Centro de Investigaciones Oncológicas Fundación Cáncer   (Argentina)

^c Hospital Eva Peron   (Argentina)

^d INSTITUTO ALEXANDER FLEMING   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GALECTIN 1; GALECTIN 3;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DNA STRAND BREAKAGE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNOLOGY; WESTERN BLOTTING;

EID: 33646509028     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.050971     Document Type: Article

References (35)

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics 2000. CA-Cancer J Clin 2000, 50:7-33
2. Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, Hercend T: Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma: evidence for in situ T cell clonal expansion. J Clin Invest 1993, 91:1183-1190
3. thor Strafen P, Guldberg P, Gronbaeck K, Hansen MR, Kirkin AF, Seremet T, Zeuthen J, Becker JC: In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol 1999, 163:443-447
4. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003, 26:332-342
5. Rosenberg SA, Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004, 101(Suppl 2):14639-14645
6. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366
7. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, Stringaro A, Molinari A, Arancia G, Gentile M, Parmiani G, Fais S: Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002, 195:1303-1316
8. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO: Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 2004, 165:1853-1863
9. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilaguerh JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004, 5:241-251
10. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A: Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000, 156:899-909
11. Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, lacobelli S: Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?: Trends Immunol 2002, 23:313-320
12. Liu F-T, Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer 2005, 5:29-41
13. Perillo NL, Pace KE, Seilhamer JJ, Baum LG: Apoptosis of T cells mediated by galectin-1. Nature 1995, 378:736-739
14. Fukumori T, Takenaka Y, Yoshii T, Choi Kim HR, Hogan V, Inohara H, Kagawa S, Raz A: CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 2003, 63:8302-8311
15. Rabinovich GA, Daly G, Dreja H, Tailor H, Riera CM, Hirabayashi J, Chernajovsky Y: Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 1999, 190:385-398
16. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A: Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997, 57:5272-5276
17. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR, Bresalier RS, Raz A: Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004, 24:4395-4406
18. Ochieng J, Green B, Evans S, James O, Warfield P: Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta 1998, 1379:97-106
19. Hofmann UB, Eggert AA, Blass K, Brocker EB, Becker JC: Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res 2003, 63:8221-8225
20. Hernandez JD, Baum LG: Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology 2002, 12:127R-136R
21. Koji T: Nonradioactive in situ nick translation: a useful molecular histochemical tool to detect single-stranded DNA breaks. Acta Histochem Cytochem 1996, 29:71-79
22. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254
23. Kockx MM, De Meyer GR, Sortier H, de Meyere N, Muhring J, Bakker A, Jacob W, Van Vaeck L, Herman A: Luminal foam cell accumulation is associated with smooth muscle cell death in the intimal thickening of human saphenous vein grafts. Circulation 1996, 94:1255-1262
24. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T: Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000, 6:3560-3564
25. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715
26. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111
27. Guevremont M, Martel-Pelletier J, Boileau C, Liu FT, Richard M, Fernandes JC, Pelletier JP, Reboul P: Galectin-3 surface expression on human adult chondrocytes: a potential substrate for collagenase-3. Ann Rheum Dis 2004, 63:636-643
28. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A: Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002, 277:6852-6857
29. Califice S, Castronovo V, Bracke M, van den Brule F: Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 2004, 23:7527-7536
30. Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG: CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol 2000, 165:2331-2334
31. Hahn HP, Pang M, He J, Hernandez JD, Yang RY, Li LY, Wang X, Liu FT, Baum LG: Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Differ 2004, 11:1277-1286
32. Nguyen JT, Evans DP, Galvan M, Pace KE, Leitenberg D, Bui TN, Baum LG: CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2-O-glycans. J Immunol 2001, 167:5697-5707
33. He J, Baum LG: Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 2004, 279:4705-4712
34. Martinez-Lorenzo MJ, Anel A, Alava MA, Pineiro A, Naval J, Lasierra P, Larrad L: The human melanoma cell line MelJuSo secretes bioactive FasL and AP02L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 2004, 295:315-329
35. - T cells in murine tumors generated independent of antigen specificity. J Immunol 2004, 172:1602-1611